352 related articles for article (PubMed ID: 24292706)
1. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.
Sim GC; Martin-Orozco N; Jin L; Yang Y; Wu S; Washington E; Sanders D; Lacey C; Wang Y; Vence L; Hwu P; Radvanyi L
J Clin Invest; 2014 Jan; 124(1):99-110. PubMed ID: 24292706
[TBL] [Abstract][Full Text] [Related]
2. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
3. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
Strauss L; Bergmann C; Szczepanski MJ; Lang S; Kirkwood JM; Whiteside TL
J Immunol; 2008 Mar; 180(5):2967-80. PubMed ID: 18292519
[TBL] [Abstract][Full Text] [Related]
4. Circulating Treg cells from patients with cerebral aneurysms displayed deficiency in ICOS expression and function.
Zhao MG; Peng C; Li LM; Chen L; Zhang HF
Clin Exp Pharmacol Physiol; 2020 Dec; 47(12):1923-1931. PubMed ID: 32726458
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
Front Immunol; 2018; 9():2227. PubMed ID: 30319662
[TBL] [Abstract][Full Text] [Related]
6. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
[TBL] [Abstract][Full Text] [Related]
7. A B-1a cell subset induces Foxp3(-) T cells with regulatory activity through an IL-10-independent pathway.
Hsu LH; Li KP; Chu KH; Chiang BL
Cell Mol Immunol; 2015 May; 12(3):354-65. PubMed ID: 25132452
[TBL] [Abstract][Full Text] [Related]
8. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
9. Multiple in vitro and in vivo regulatory effects of budesonide in CD4+ T lymphocyte subpopulations of allergic asthmatics.
Pace E; Di Sano C; La Grutta S; Ferraro M; Albeggiani G; Liotta G; Di Vincenzo S; Uasuf CG; Bousquet J; Gjomarkaj M
PLoS One; 2012; 7(12):e48816. PubMed ID: 23251336
[TBL] [Abstract][Full Text] [Related]
10. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
11. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice.
Kornete M; Sgouroudis E; Piccirillo CA
J Immunol; 2012 Feb; 188(3):1064-74. PubMed ID: 22227569
[TBL] [Abstract][Full Text] [Related]
12. [Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].
Wang ZH; Zhu JY; Li T; Leng XS
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):844-7. PubMed ID: 18756991
[TBL] [Abstract][Full Text] [Related]
13. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.
Chen Y; Shen S; Gorentla BK; Gao J; Zhong XP
J Immunol; 2012 Feb; 188(4):1698-707. PubMed ID: 22231701
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating mast cells stimulate ICOS
Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
[TBL] [Abstract][Full Text] [Related]
16. CD4⁺Foxp3⁺ Treg and its ICOS⁺ subsets in patients with myocardial infarction.
Ghourbani Gazar S; Andalib A; Hashemi M; Rezaei A
Iran J Immunol; 2012 Mar; 9(1):53-60. PubMed ID: 22426168
[TBL] [Abstract][Full Text] [Related]
17. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.
Zheng J; Chan PL; Liu Y; Qin G; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
PLoS One; 2013; 8(12):e82203. PubMed ID: 24312642
[TBL] [Abstract][Full Text] [Related]
18. Suppressive IL-17A
Downs-Canner S; Berkey S; Delgoffe GM; Edwards RP; Curiel T; Odunsi K; Bartlett DL; Obermajer N
Nat Commun; 2017 Mar; 8():14649. PubMed ID: 28290453
[TBL] [Abstract][Full Text] [Related]
19. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D Supplementation Modulates ICOS+ and ICOS- Regulatory T Cell in Siblings of Children With Type 1 Diabetes.
Savastio S; Cadario F; D'Alfonso S; Stracuzzi M; Pozzi E; Raviolo S; Rizzollo S; Gigliotti L; Boggio E; Bellomo G; Basagni C; Bona G; Rabbone I; Dianzani U; Prodam F
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32844222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
